IP Verse

Pharmaceutical Compounds For Use In The Therapy Of Clostridium Difficile Infection - EP2773648

The patent EP2773648 was granted to ETH Zrich on Mar 13, 2019. The application was originally filed on Sep 28, 2012 under application number EP12772882A. The patent is currently recorded with a legal status of "Opposition Rejected".

EP2773648

ETH ZRICH
Application Number
EP12772882A
Filing Date
Sep 28, 2012
Status
Opposition Rejected
Jul 9, 2021
Grant Date
Mar 13, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

MULLER BORE & PARTNER PATENTANWALTE PARTG MBBDec 12, 2019-ADMISSIBLE

Patent Citations (3) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTUS2010048730
INTERNATIONAL-SEARCH-REPORTWO2010049921
INTERNATIONAL-SEARCH-REPORTWO2012138963

Non-Patent Literature (NPL) Citations (23) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- D. LAMPE; C. LIU; B. V. L. POTTER, J. MED. CHEM., (1994), vol. 37, page 907-
DESCRIPTION- EGERER ET AL., PLOS PATHOG., (2010), vol. 6, page E1000942-
DESCRIPTION- MARTIN, S. F. ET AL., J. ORG. CHEM., (1994), vol. 59, page 4805-
DESCRIPTION- NAUNYN-SCHMIEDEBERG'S ARCH. PHARMACOL., (2011), vol. 383, page 253-
DESCRIPTION- OUDSHORN ET AL., BIOMATERIALS, (2006), vol. 27, pages 5471 - 5479-
DESCRIPTION- REINEKE ET AL., NATURE, (2007), vol. 446, page 415-
DESCRIPTION- SHEN, NAT. STRUCT. MOL. BIOL., (2011), vol. 18, page 364-
DESCRIPTION- VOTH; BALLARD, CLINICAL MICROBIOLOGY REVIEWS, (2005), vol. 18, pages 247 - 263-
DESCRIPTION- WILMS ET AL., ACC. CHEM. RES., (2010), vol. 43, pages 129 - 41-
INTERNATIONAL-SEARCH-REPORT- FLORIN I ET AL, "Polyphosphate-mediated protection from cellular intoxication with Clostridium difficile toxin B", BIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR CELL RESEARCH, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 805, no. 2, doi:10.1016/0167-4889(84)90159-9, ISSN 0167-4889, (19841012), pages 131 - 136, (19841012), XP025401706 [X] 16,17 * page 131 * * page 133; table I * [A] 6,9 [I] 1-5,7,8,10-15,18,19
INTERNATIONAL-SEARCH-REPORT- G. GUTTENBERG ET AL, "Inositol Hexakisphosphate-dependent Processing of Clostridium sordellii Lethal Toxin and Clostridium novyi -Toxin", JOURNAL OF BIOLOGICAL CHEMISTRY, (20110429), vol. 286, no. 17, doi:10.1074/jbc.M110.200691, ISSN 0021-9258, pages 14779 - 14786, XP055046383 [A] 1-19 * page 14784; figure 5 *
OPPOSITION- WEINHART et al., "Linear Poly(methyl glycerol) and Linear Polyglycerol as Potent Protein and Cell Resistant Alternatives to Poly(ethylene glycol", Chem. Asian J., (20100000), vol. 5, doi:10.1002/asia.201000127, pages 1992 - 2000, XP008158617
OPPOSITION- KREIMEYER I. et al., "Autoproteolytic cleavage mediates cytotoxicity of Clostrid- ium difficile toxin A", Naunyn-Schmied Arch Pharmacol, vol. 383, (20110000), pages 253 - 262, (20101103), XP019883967
OPPOSITION- FLORIN I. et al., "Polyphosphate-mediated protection from cellular intoxication with Clostridium difficile toxin B", Biochimica et Biophysica Acta, (19840000), vol. 805, no. 2, doi:10.1016/0167-4889(84)90159-9, pages 131 - 136, XP025401706
OPPOSITION- KAINTHAN R. K. et al., "In vitro biological evaluation of high molecular weight hy- perbranched polyglycerols", Biomaterials, (20070000), vol. 28, doi:10.1016/j.biomaterials.2007.07.011, pages 4581 - 4590, XP022206998
OPPOSITION- MINKO T., "Soluble polymer conjugates for drug delivery", Drug Discovery To- day: Technologies, (20050000), vol. 2, no. 1, doi:10.1016/j.ddtec.2005.05.005, pages 15 - 20, XP004985723
OPPOSITION- GIGER W et al., "Gene delivery with bisphosphonate-stabilized calcium phosphate nanoparticles", Gene delivery with bisphosphonate-stabilized calcium phosphate nanoparticles, vol. 150, no. 1, (20110000), pages 87 - 93, (20101124), XP055012163
OPPOSITION- HUANG X et al., "Preparation of Pegylated chelator-stabilized calcium phospahte nanoparticles for liver-targeted delivery nucleic acid", Abstracts/J Controlled Release, (20150000), vol. 213, pages e-8 - e 152150 , 87-93, XP029259288
OPPOSITION- GREENWALD R. et al., "Effective drug delivery by PEGylated drug conjugates", Adv Drug Delivery Rev, (20030000), vol. 55, doi:10.1016/S0169-409X(02)00180-1, pages 217 - 250, XP002400503
OPPOSITION- GUTTENBERG G. et al., "Inositol Hexakisphosphate-dependent Processing of Clostridium sordellii Lethal Toxin and Clostridium novyi á-Toxin", Journal of Biological Chemistry, (20110429), vol. 286, no. 17, doi:10.1074/jbc.M110.200691, pages 14779 - 14786, XP055046383
OPPOSITION- HAMIDI. M. et al., "Pharmacokinetic Consequences of Pegylation", Drug Deliv- ery, (20060000), vol. 13, doi:10.1080/10717540600814402, pages 399 - 409, XP055531921
OPPOSITION- BAILON P. et al., "PEG-modified biopharmaceuticals", Expert Opin. Drug Deliv., (20090000), vol. 6, no. 1, doi:10.1517/17425240802650568, pages 1 - 16, XP008108163
OPPOSITION- VERONESE F. M. et al., "The Impact of PEGylation on Biological Therapies", Bio- drugs, (20080000), vol. 22, no. 5, doi:10.2165/00063030-200822050-00004, pages 315 - 329, XP009116032

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents